文献速递妇科肿瘤

帕博利珠单抗联合化疗序贯帕博利珠单抗±奥拉帕利一线治疗BRCA未突变晚期上皮性卵巢癌的III期随机双盲安慰剂对照试验

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2026-09-07

ENGOT-OV43/GOG-3036/KEYLYNK-001研究纳入1367例BRCA未突变晚期上皮性卵巢癌患者,随机接受帕博利珠单抗+化疗序贯帕博利珠单抗+奥拉帕利、帕博利珠单抗+化疗序贯帕博利珠单抗+安慰剂或安慰剂+化疗序贯安慰剂。

要点

  • 帕博利珠单抗-奥拉帕利组3级及以上治疗相关不良事件发生率66%

核心结论

  • 帕博利珠单抗联合化疗序贯帕博利珠单抗-奥拉帕利维持较单纯化疗显著改善BRCA未突变晚期上皮性卵巢癌患者的PFS。
  • 帕博利珠单抗单药方案较对照组未显示显著PFS获益。

研究设计与样本

  • 随机、双盲、活性对照、安慰剂对照III期试验,在22个国家224个妇科肿瘤中心开展。
  • 纳入1367例BRCA未突变III-IV期上皮性卵巢癌、原发性腹膜癌或输卵管癌患者,按1:1:1随机分配。
  • 三组分别为帕博利珠单抗-奥拉帕利组(n=455)、帕博利珠单抗组(n=458)和对照组(n=454)。
  • 主要终点为PFS,采用分层检验策略,先在CPS≥10人群后在意向治疗人群检验。

主要发现

  • 帕博利珠单抗-奥拉帕利组、帕博利珠单药组和对照组3级及以上治疗相关不良事件发生率分别为66%、56%和51%,最常见为中性粒细胞减少(23%、17%、20%)、贫血(22%、13%、11%)和中性粒细胞计数降低(15%、15%、15%)。
  • 严重治疗相关不良事件发生率分别为24%、21%和9%,最常见为发热性中性粒细胞减少(4%、4%、2%);治疗相关不良事件导致死亡分别为4例(1%)、1例(<1%)和0例。

关键数值与推荐

  • 入组标准:年龄≥18岁,组织学确诊III-IV期上皮性卵巢癌、原发性腹膜癌或输卵管癌且无BRCA突变,ECOG PS 0-1,未接受过抗PD-1/PD-L1/PD-L2、PARP抑制剂等治疗。
  • 治疗方案:静脉帕博利珠单抗200 mg(或安慰剂)每3周一次共35周期;卡铂+紫杉醇(或多西他赛)化疗5周期;维持口服奥拉帕利300 mg(或安慰剂)每日两次至停药或最长2年。
  • 随机分层因素:PD-L1 CPS(<10 vs ≥10)、计划使用贝伐珠单抗、手术状态。

临床怎么用

  • 对于BRCA未突变晚期上皮性卵巢癌一线治疗,帕博利珠单抗联合化疗序贯帕博利珠单抗-奥拉帕利维持可作为潜在治疗选择,尤其PD-L1 CPS≥10人群获益更明显。
  • 帕博利珠单抗单药方案未显示显著PFS获益,不支持在该人群中使用帕博利珠单抗单药维持。
  • 该方案3级及以上治疗相关不良事件发生率较高(66%),需密切监测血液学毒性及严重不良事件。

局限性

  • 帕博利珠单抗单药组在CPS≥10人群PFS无显著获益,故未在ITT人群进行正式检验。
  • 最终分析时总生存数据未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PARP inhibitor olaparib is used for first-line maintenance of patients with BRCA-mutated advanced ovarian cancer. We aimed to evaluate the efficacy and safety of pembrolizumab plus chemotherapy followed by pembrolizumab plus olaparib maintenance with or without bevacizumab as first-line treatment for patients with advanced BRCA1/2 non-mutated epithelial ovarian cancer. METHODS: This randomised, double-blind, active-controlled, placebo-controlled, phase 3 trial was conducted at 224 gynaecological oncology centres in 22 countries. Eligible participants were aged 18 years or older; had histologically confirmed stage III-IV epithelial ovarian, primary peritoneal, or fallopian tube cancer with no BRCA mutation; did not receive previous anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy or an agent directed at another stimulatory or coinhibitory T-cell receptor or a PARP inhibitor; had an Eastern Cooperative Oncology Group performance status score of 0 or 1; and evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST). After one lead-in chemotherapy cycle, participants were randomly assigned (1:1:1), using an integrated interactive voice and web response system, to receive pembrolizumab plus chemotherapy followed by pembrolizumab plus olaparib maintenance (pembrolizumab-olaparib group); pembrolizumab plus chemotherapy followed by pembrolizumab plus placebo maintenance (pembrolizumab group); or placebo plus chemotherapy followed by placebo maintenance (control group); and could receive bevacizumab at the investigators discretion. Treatment allocation was stratified by PD-L1 combined positive score (CPS <10 vs ≥10), planned bevacizumab use, and surgery status. Planned treatment was intravenous pembrolizumab 200 mg (or matching placebo) every 3 weeks for 35 cycles, carboplatin plus paclitaxel (or docetaxel) chemotherapy according to local standard of care for five cycles, and maintenance oral olaparib 300 mg (or matching placebo) twice per day until discontinuation or up to 2 years. The primary endpoint was progression-free survival, tested first in the CPS (≥10) population and then in the intention-to-treat (ITT) population using a hierarchical testing strategy. This study is registered with ClinicalTrials.gov, NCT03740165 and is complete. FINDINGS: Between Jan 30, 2019, and Aug 6, 2021, 2547 patients were assessed for eligibility, and 1367 were randomly assigned (ITT population) to receive pembrolizumab-olaparib (n=455), pembrolizumab (n=458), or the control (n=454). All participants were female and the median age was 61 years (IQR 52-68). 1084 (79%) of 1364 participants were White, 233 (17%) were Asian, 27 (2%) were of multiple race, 15 (1%) were Black or African American, and 5 (<1%) were American Indian or Alaska Native. At the first interim analysis (Jan 9, 2023; median follow-up 30·1 months [IQR 23·9-37·0]), pembrolizumab-olaparib significantly improved progression-free survival versus the control in the CPS (≥10; HR 0·63 [95% CI 0·49-0·80]; p<0·0001) and ITT populations (HR 0·68 [0·58-0·81]; p<0·0001). At the final analysis (Aug 26, 2024; median follow-up 49·6 months [IQR 43·4-56·5]), progression-free survival with pembrolizumab-olaparib was maintained (HR 0·66 [95% CI 0·53-0·83] in the CPS [≥10] population and 0·71 [0·61-0·84] in the ITT population). Pembrolizumab alone compared with the control group remained non-significant in the CPS (≥10) population (HR 0·95 [0·77-1·19]; p=0·33); therefore, there was no formal testing of progression-free survival in the ITT population. 297 (66%) of 452 participants in the pembrolizumab-olaparib group, 255 (56%) of 456 in the pembrolizumab group, and 232 (51%) of 454 in the control group had a grade 3 or higher treatment-related adverse event; the most common being neutropenia (102 [23%], 78 [17%], and 89 [20%]), anaemia (100 [22%], 59 [13%], and 48 [11%]), and neutrophil count decreased (66 [15%], 66 [15%], 68 [15%]). Serious treatment-related adverse events were reported in 110 (24%) participants in the pembrolizumab-olaparib group, 96 (21%) in the pembrolizumab group, and 39 (9%) in the control group, with the most common being febrile neutropenia (19 [4%], 16 [4%], and nine [2%]). Treatment-related adverse events led to death in four (1%) participants in the pembrolizumab-olaparib group (cerebral haemorrhage, cholangitis sclerosing, haemophagocytic lymphohistiocytosis, and colitis), and one (<1%) in the pembrolizumab group (gastrointestinal haemorrhage). INTERPRETATION: Pembrolizumab plus chemotherapy followed by maintenance with pembrolizumab-olaparib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy, suggesting that this regimen might have potential for patients with newly diagnosed BRCA non-mutated stage III-IV epithelial ovarian cancer. FUNDING: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Vergote I, Cibula D, Powell M, et al. Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2026. PMID: 42705254. doi:10.1016/S1470-2045(26)00223-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。